CDH1 gene as a prognostic biomarker in HCV (genotype 4) induced hepatocellular carcinoma in the Egyptian patients
CDH1 gene as a prognostic biomarker in HCV (genotype 4) induced hepatocellular carcinoma in the Egyptian patients
复制标题
DOI：
10.1016/j.genrep.2019.100452
复制
发表时间：
2019-09-01
期刊：
影响因子：
1.3
通讯作者：
Essawy, Faiza M.
中科院分区：
文献类型：
--
作者：
El-Araby, Rady E.;Khalifa, Mahmoud A.;Essawy, Faiza M.
肝细胞癌（HCC）患者由于在最后阶段才被诊断，因此预后工具匮乏。因此，寻找有效的生物标志物，对肝癌的诊断和治疗至关重要。在目前的工作中，我们研究了原型I型钙粘蛋白（CDH 1）的表达在慢性肝病（CLD）由于HCV基因型4感染/无肝硬化和HCC患者作为一种尝试，以评估这种新的循环，非侵入性，预后，生物标志物肝硬化和癌变的埃及患者的潜在利益。80例受试者被纳入本研究，分为两组; I组（40例患者）被分为Ia组（CLD无肝硬化，n = 18）和Ib组（CLD伴肝硬化，n = 22），II组（CLD伴HCC患者，n = 20）和对照组（健康志愿者，n = 20）。Real-Time PCR检测CDH 1基因的表达。CDH 1在所有患病组中显示出持续和显著的下调，这与疾病向HCC阶段的进展不一致。此外，它显示了区分HCC与CLD伴/不伴肝硬化的诊断能力（p < 0.001）。CDH 1基因可作为HCC的预测因子和预后指标（OR = 0.15，95% CI 0.033-0.677，p = 0.01），但不适合作为HCC的预测因子。最后，随着疾病进展，CDH 1基因表达逐渐下降，提示我们将其用作HCV基因型4患者中HCV诱导的肝硬化和HCC的非侵入性预后生物标志物。
Patients with hepatocellular carcinoma (HCC) have indigent in prognosis tools due to being diagnosed at the latest stages. Its crucial to identify efficient biomarkers that can get better overall diagnosis and treatment of HCC. In the current work, we examined prototypical type I cadherin (CDH1) expression in chronic liver disease (CLD) due to HCV genotype 4 infection with/without cirrhosis and HCC patients as an attempt to evaluate the potential benefits of this new circulating, noninvasive, prognostic, biomarkers for liver cirrhosis and carcinogenesis of Egyptian patients. Eighty subjects were included in this study, divided into two groups; Group I (40 patients) were classified into Group Ia (CLD without cirrhosis, n = 18) and Group Ib (CLD with cirrhosis, n = 22), Group II (CLD patients with HCC, n = 20), and control (Healthy volunteer, n = 20). The expression of CDH1 gene was analyzed by Real-Time PCR. CDH1 showed a persistent and significant downregulation in all diseased groups, which was inconsistency with the progression of the disease toward the HCC stage. In addition, it showed a diagnostic ability to discriminate between cases of HCC against CLD with/without cirrhosis (p < 0.001). Furthermore, CDH1 gene could be considered as a predictor and prognostic parameters for HCC (OR = 0.15, 95% CI 0.033-0.677, p = 0.01), but it was not suitable for use as a predictor for cirrhotic patients. Finally, the gradual decline of CDH1 gene expression with disease progression prompts us to use it as noninvasive prognostic biomarkers for HCV induced liver cirrhosis and HCC in HCV Genotype 4 patients.